SCHEMBL11296451

SCHEMBL11296451

CNC(C)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.50
ALDH1A1 P00352 2/20 0.47
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ACACB O00763 2/20 0.45
ACACA Q13085 2/20 0.45
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
GRIA4 P48058 1/20 0.43
PRCP P42785 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4318 0.85 CYP3A4 (0.54) ALDH1A1MAPTHPGDCYP3A4CYP2D6
SCHEMBL21533 0.85 CYP3A4 (0.54) ALDH1A1MAPTHPGDCYP3A4CYP2D6
SCHEMBL6133 0.85 CYP3A4 (0.54) ALDH1A1MAPTHPGDCYP3A4CYP2D6
Hydrochloric Acid SCHEMBL28141900 0.83 KMT2A (0.56) ALDH1A1MAPTHPGDCYP3A4CYP2D6
Methane SCHEMBL28682583 0.83 CYP3A4 (0.52) ALDH1A1MAPTHPGDCYP3A4CYP2D6
SCHEMBL12417430 0.82 PTGS2 (0.50) PTGS2ALDH1A1MAPTHPGDACACB
SCHEMBL27629222 0.80 PTGS2 (0.48) PTGS2ALDH1A1MAPTHPGDACACB
SCHEMBL24398870 0.78 CYP3A4 (0.48) PTGS2ALDH1A1MAPTHPGDCYP3A4
SCHEMBL13824244 0.78 ADRA2C (0.53) ALDH1A1MAPTHPGDCYP3A4CYP2D6
SCHEMBL8693501 0.77 ACACB (0.57) ALDH1A1HPGDACACBACACASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2665706-A1 NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2013-11-27 EP disclosed
WO-2012098132-A1 NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-7713961-B2 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-11 US disclosed
US-20090325940-A1 Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325940-A1 Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof PSEN1, PSEN2, BACE1 PTGS2 2860/4885ALDH1A1 511/4885MAPT 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.